Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Genetics of Lipoprotein(a) : Cardiovascular Disease and Future Therapy. / Langsted, Anne; Nordestgaard, Børge G.
I: Current Atherosclerosis Reports, Bind 23, Nr. 8, 46, 2021.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Genetics of Lipoprotein(a)
T2 - Cardiovascular Disease and Future Therapy
AU - Langsted, Anne
AU - Nordestgaard, Børge G.
N1 - Publisher Copyright: © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021
Y1 - 2021
N2 - Purpose of Review: Lipoprotein(a) levels are determined 80–90% by genetics and differ by up to 1000-fold between individuals. This review discusses the most recent literature on lipoprotein(a) as a risk factor for cardiovascular disease, as well as future lipoprotein(a)lowering therapies. Recent Findings: Over the past few decades, numerous studies have observed that high lipoprotein(a) levels are associated observationally and causally through human genetics with increased risk of cardiovascular disease. Also, the development of safe and effective therapies to lower lipoprotein(a) is ongoing, most importantly using antisense oligonucleotides to prevent production of lipoprotein(a). Finally, both observational and genetic studies have estimated the extent to which lowering of lipoprotein(a) is needed to obtain a clinically meaningful reduction in the risk of cardiovascular disease. Summary: Lipoprotein(a) is a causal risk factor for cardiovascular disease; however, currently no approved safe and effective therapy is available to lower lipoprotein(a) levels. That said, promising randomized studies using antisense oligonucleotides show up to 80% reductions in lipoprotein(a), reductions that hopefully will result in lowering the risk of cardiovascular disease as presently tested in the ongoing HORIZON phase 3 trial.
AB - Purpose of Review: Lipoprotein(a) levels are determined 80–90% by genetics and differ by up to 1000-fold between individuals. This review discusses the most recent literature on lipoprotein(a) as a risk factor for cardiovascular disease, as well as future lipoprotein(a)lowering therapies. Recent Findings: Over the past few decades, numerous studies have observed that high lipoprotein(a) levels are associated observationally and causally through human genetics with increased risk of cardiovascular disease. Also, the development of safe and effective therapies to lower lipoprotein(a) is ongoing, most importantly using antisense oligonucleotides to prevent production of lipoprotein(a). Finally, both observational and genetic studies have estimated the extent to which lowering of lipoprotein(a) is needed to obtain a clinically meaningful reduction in the risk of cardiovascular disease. Summary: Lipoprotein(a) is a causal risk factor for cardiovascular disease; however, currently no approved safe and effective therapy is available to lower lipoprotein(a) levels. That said, promising randomized studies using antisense oligonucleotides show up to 80% reductions in lipoprotein(a), reductions that hopefully will result in lowering the risk of cardiovascular disease as presently tested in the ongoing HORIZON phase 3 trial.
KW - Aortic stenosis
KW - Atherosclerosis
KW - Epidemiology
KW - Genetics
KW - KIV-2
KW - Lp(a)
KW - Mendelian randomization
KW - Myocardial infarction
KW - Stroke
U2 - 10.1007/s11883-021-00937-0
DO - 10.1007/s11883-021-00937-0
M3 - Review
C2 - 34148150
AN - SCOPUS:85108508383
VL - 23
JO - Current Atherosclerosis Reports
JF - Current Atherosclerosis Reports
SN - 1523-3804
IS - 8
M1 - 46
ER -
ID: 273643662